-
Ohr Pharmaceutical Reports Fiscal First Quarter 2018 Financial Results
-
Roth Capital Downgrades Ohr Pharmaceutical (OHRP) to Neutral Following MAKO Results
-
Roth Capital Reiterates Buy on Ohr Pharmaceutical (OHRP) Ahead of MAKO Results
-
Pre-Open Movers 11/27: (OHRP) (CUDA) (TIME) Higher; (SEDG) (SQ) (WDC) Lower (more...)
-
Roth Capital Starts Ohr Pharmaceutical (OHRP) at Buy
-
Roth Capital Resumes Ohr Pharmaceutical (OHRP) at 'Buy'; Believes Market Undervaluing Potential
-
Ohr Pharmaceutical (OHRP) Bullish Stance Reiterated at Roth Capital Following Encouraging Data
-
Notable Analyst Rating Changes 2/26: (AXP) (TMUS) (JAKK) Upgraded; (PCRX) (CVC) (PGRE) Downgraded
-
Pre-Open Stock Movers 02/26: (ELX) (CYBX) (UIL) (CRM) Higher; (CLRX) (LKQ) (TASR) Lower (more...)
-
Roth Capital Starts Ohr Pharmaceutical (OHRP) at Buy
-
Ohr Pharmaceutical (OHRP) Closes 4.26M Common Offering; Gross Proceeds at ~$28.8M
-
Ohr Pharmaceutical (OHRP) Prices 3.7M Common Offering at $6.75/Share

